Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment.

Gynecol Oncol Rep

Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy.

Published: May 2019

Background: Luteinized thecoma with sclerosing peritonitis (LTSP) is a very rare condition, and its clinical management is not evidence-based. Here we describe a case of long-term disease control achieved with leuprorelin and tamoxifen therapy.

Case Presentation: A 18-year-old woman with acute abdomen underwent surgical removal of an ovarian mass and received diagnosis of LTSP. Treatment plan consisted of leuprorelin and tamoxifen, followed by a good instrumental response. After 5 years, leuprorelin was stopped, and the patient continued tamoxifen alone. Ten years after diagnosis, she is still disease free.

Conclusion: Even in the absence of solid evidence, the combination of leuprorelin and tamoxifen could be considered as a possible medical treatment of LTSP. Considering the limitations related to the rarity of disease, further studies are needed to improve its management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396082PMC
http://dx.doi.org/10.1016/j.gore.2019.02.004DOI Listing

Publication Analysis

Top Keywords

leuprorelin tamoxifen
16
luteinized thecoma
8
thecoma sclerosing
8
sclerosing peritonitis
8
leuprorelin
5
tamoxifen
5
long term
4
term control
4
control luteinized
4
peritonitis leuprorelin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!